Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation

Jamie Smith,1 Charles Leonard,1 Dennis L Carter,2 Shannon Tole1 1Rocky Mountain Cancer Centers Littleton, Denver, CO, USA; 2Rocky Mountain Cancer Centers Aurora, Denver, Co, USACorrespondence: Jamie SmithRocky Mountain Cancer Centers Littleton, 790 Fillmore St., Denver, Co, 80206, USATel +1 303-304-...

Full description

Bibliographic Details
Main Authors: Smith J, Leonard C, Carter DL, Tole S
Format: Article
Language:English
Published: Dove Medical Press 2021-08-01
Series:Breast Cancer : Targets and Therapy
Subjects:
Online Access:https://www.dovepress.com/does-the-presence-of-cytokeratin-positive-individual-tumor-cells-n0i-i-peer-reviewed-fulltext-article-BCTT
id doaj-289394328a2846559a0bb8f9193e9fa5
record_format Article
spelling doaj-289394328a2846559a0bb8f9193e9fa52021-08-29T20:18:51ZengDove Medical PressBreast Cancer : Targets and Therapy1179-13142021-08-01Volume 1351351768319Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast IrradiationSmith JLeonard CCarter DLTole SJamie Smith,1 Charles Leonard,1 Dennis L Carter,2 Shannon Tole1 1Rocky Mountain Cancer Centers Littleton, Denver, CO, USA; 2Rocky Mountain Cancer Centers Aurora, Denver, Co, USACorrespondence: Jamie SmithRocky Mountain Cancer Centers Littleton, 790 Fillmore St., Denver, Co, 80206, USATel +1 303-304-1187Email 1007jamiesmith@gmail.comPurpose: To report a primary objective clinical outcome of ipsilateral breast cancer recurrence following accelerated partial breast irradiation (APBI) with N0(i+) (single tumor cells or clusters < 2mm) in sentinel lymph nodes. The secondary objective was to observe any incidence of ipsilateral breast failure.Patients and Methods: Between March 2004 and April 2016, a total of 747 patients were enrolled in one of two APBI (Accelerated Partial Breast Irradiation) breast protocols (Phase II NCT01185145 and Phase III NCT01185132). Nineteen patients with N0(i+) disease were treated between February 2005 and December 2015. Patient eligibility included a primary invasive or DCIS tumor size < 3 cm, N0(i+) disease, and margin width of > 2 mm. All enrolled patients presented in this report had sentinel lymph node examinations. Clinical outcomes of ipsilateral breast, axillary and combined regional (breast or axillary) recurrences were analyzed.Results: Median follow-up for all patients was 5 years (1– 8 years). No patient experienced either ipsilateral breast or axillary recurrence.Conclusion: There has been scarce information/reporting of the treatment of patients with cytokeratin positive individual tumor cells N0(i+) with APBI. The authors have presented data which suggest that the successful outcomes of these patients might warrant further study.Keywords: breast sentinel nodes, breast conservation therapyhttps://www.dovepress.com/does-the-presence-of-cytokeratin-positive-individual-tumor-cells-n0i-i-peer-reviewed-fulltext-article-BCTTbreast sentinel nodesbreast conservation therapy
collection DOAJ
language English
format Article
sources DOAJ
author Smith J
Leonard C
Carter DL
Tole S
spellingShingle Smith J
Leonard C
Carter DL
Tole S
Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation
Breast Cancer : Targets and Therapy
breast sentinel nodes
breast conservation therapy
author_facet Smith J
Leonard C
Carter DL
Tole S
author_sort Smith J
title Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation
title_short Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation
title_full Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation
title_fullStr Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation
title_full_unstemmed Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation
title_sort does the presence of cytokeratin positive individual tumor cells (n0(i+)) in sentinel lymph nodes affect clinical outcomes in breast cancer patients treated with accelerated partial breast irradiation
publisher Dove Medical Press
series Breast Cancer : Targets and Therapy
issn 1179-1314
publishDate 2021-08-01
description Jamie Smith,1 Charles Leonard,1 Dennis L Carter,2 Shannon Tole1 1Rocky Mountain Cancer Centers Littleton, Denver, CO, USA; 2Rocky Mountain Cancer Centers Aurora, Denver, Co, USACorrespondence: Jamie SmithRocky Mountain Cancer Centers Littleton, 790 Fillmore St., Denver, Co, 80206, USATel +1 303-304-1187Email 1007jamiesmith@gmail.comPurpose: To report a primary objective clinical outcome of ipsilateral breast cancer recurrence following accelerated partial breast irradiation (APBI) with N0(i+) (single tumor cells or clusters < 2mm) in sentinel lymph nodes. The secondary objective was to observe any incidence of ipsilateral breast failure.Patients and Methods: Between March 2004 and April 2016, a total of 747 patients were enrolled in one of two APBI (Accelerated Partial Breast Irradiation) breast protocols (Phase II NCT01185145 and Phase III NCT01185132). Nineteen patients with N0(i+) disease were treated between February 2005 and December 2015. Patient eligibility included a primary invasive or DCIS tumor size < 3 cm, N0(i+) disease, and margin width of > 2 mm. All enrolled patients presented in this report had sentinel lymph node examinations. Clinical outcomes of ipsilateral breast, axillary and combined regional (breast or axillary) recurrences were analyzed.Results: Median follow-up for all patients was 5 years (1– 8 years). No patient experienced either ipsilateral breast or axillary recurrence.Conclusion: There has been scarce information/reporting of the treatment of patients with cytokeratin positive individual tumor cells N0(i+) with APBI. The authors have presented data which suggest that the successful outcomes of these patients might warrant further study.Keywords: breast sentinel nodes, breast conservation therapy
topic breast sentinel nodes
breast conservation therapy
url https://www.dovepress.com/does-the-presence-of-cytokeratin-positive-individual-tumor-cells-n0i-i-peer-reviewed-fulltext-article-BCTT
work_keys_str_mv AT smithj doesthepresenceofcytokeratinpositiveindividualtumorcellsn0iinsentinellymphnodesaffectclinicaloutcomesinbreastcancerpatientstreatedwithacceleratedpartialbreastirradiation
AT leonardc doesthepresenceofcytokeratinpositiveindividualtumorcellsn0iinsentinellymphnodesaffectclinicaloutcomesinbreastcancerpatientstreatedwithacceleratedpartialbreastirradiation
AT carterdl doesthepresenceofcytokeratinpositiveindividualtumorcellsn0iinsentinellymphnodesaffectclinicaloutcomesinbreastcancerpatientstreatedwithacceleratedpartialbreastirradiation
AT toles doesthepresenceofcytokeratinpositiveindividualtumorcellsn0iinsentinellymphnodesaffectclinicaloutcomesinbreastcancerpatientstreatedwithacceleratedpartialbreastirradiation
_version_ 1721186195166199808